Terumo Blood and Cell Technologies (Terumo BCT) and PwC Belgium have partnered to improve access to advanced cell and gene therapies in Europe. This joint effort seeks to address existing barriers that prevent patients from receiving cutting-edge medical treatments.
The partnership will kick off with an event in Brussels on Dec. 11, 2025, where industry leaders will discuss challenges in patient access to therapies. Key topics will include treatment capacity, funding systems, logistics and awareness in underserved areas.
Veerle D’Haenens, general manager, Global Therapy Innovations at Lakewood-based Terumo BCT, stated, “By joining forces with PwC Belgium, we are building a platform for meaningful change.”
Currently, only 20% to 30% of eligible patients in Europe have access to advanced therapies. The outcome of the December event is expected to lead to a multi-stakeholder consortium aimed at further improving access to these vital treatments.
